Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neoantigen Cancer Vaccine Market Snapshot
Chapter 4. Global Neoantigen Cancer Vaccine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Technology Advancement in Neoantigen Cancer Vaccine
4.9. Key Trends in the Funding and Expansion Activities
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share,2022 & 2028
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2028 for the following Product:
5.2.1. Personalized neoantigens vaccines
5.2.2. Off-the-shelf Neoantigen vaccines
Chapter 6. Neoantigen Cancer Vaccine Market Segmentation 2: Neovaccine Types (Biological Platform) Estimates & Trend Analysis
6.1. Neovaccine Types (Biological Platform) Analysis & Market Share,2022 & 2028
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2028 for the following Neovaccine Types (Biological Platform):
6.2.1. Nucleic acid/DNA/mRNA Vaccine
6.2.2. Peptide Vaccines
6.2.3. Dendritic Cell–based Vaccines
Chapter 7. Neoantigen Cancer Vaccine Market Segmentation 2: Therapy Type Estimates & Trend Analysis
7.1. Therapy Type Analysis & Market Share,2022 & 2028
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2028 for the following Therapy Type:
7.2.1. Mono Therapeutic Regimens
7.2.2. Combinatorial Regimens
Chapter 8. Neoantigen Cancer Vaccine Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by product, 2022-2028
8.1.2. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by neovaccine types, 2022-2028
8.1.3. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by therapy types, 2022-2028
8.1.4. North America Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by country, 2022-2028
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) by product, 2022-2028
8.2.2. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by neovaccine types, 2022-2028
8.2.3. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by therapy types, 2022-2028
8.2.4. Europe Neoantigen Cancer Vaccine Market revenue (US$ Million) by country, 2022-2028
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) by product, 2022-2028
8.3.2. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) estimates and forecasts by neovaccine types, 2022-2028
8.3.3. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) by therapy type, 2022-2028
8.3.4. Asia Pacific Neoantigen Cancer Vaccine Market revenue (US$ Million) by country, 2022-2028
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Rest of World
8.4.1. Rest of World Neoantigen Cancer Vaccine Market revenue (US$ Million) by product, (US$ Million)
8.4.2. Rest of World Neoantigen Cancer Vaccine Market revenue (US$ Million) by therapy type, (US$ Million)
8.4.3. Rest of World Neoantigen Cancer Vaccine Market revenue (US$ Million) by country, (US$ Million) 2022-2028
8.4.3.1. GCC Countries
8.4.3.2. Africa
8.4.3.3. Brazil
8.4.3.4. Rest of Latin America
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Roche
9.2.2. Medimmune
9.2.3. Moderna Therapeutics/Merck
9.2.4. Advaxis
9.2.5. Agenus
9.2.6. Genocea Biosciences Inc
9.2.7. Gritstone Oncology
9.2.8. Neon Therapeutics
9.2.9. Nouscom
9.2.10. OSE Immunotherapeutics
9.2.11. Immunovative Therapeutics
9.2.12. Medigene
9.2.13. Vaccibody
9.2.14. Brightpath Biotherapeutics
9.2.15. Geneos Therapeutics
9.2.16. Frame Therapeutics
9.2.17. Immunetune
9.2.18. NeoPhore
9.2.19. CureVac AG
9.2.20. Other Prominent Players